Amgen Ownership
| AMGN Stock | USD 294.53 4.63 1.60% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 541 M | Current Value 542 M | Avarage Shares Outstanding 726 M | Quarterly Volatility 150.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Amgen |
Amgen Stock Ownership Analysis
About 81.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.12. Amgen Inc recorded earning per share (EPS) of 7.83. The entity last dividend was issued on the 18th of November 2024. The firm had 2:1 split on the 22nd of November 1999. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 24200 people. For more info on Amgen Inc please contact Robert Bradway at 805 447 1000 or go to https://www.amgen.com.Besides selling stocks to institutional investors, Amgen also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Amgen's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Amgen's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Amgen Quarterly Liabilities And Stockholders Equity |
|
Amgen Insider Trades History
Less than 1% of Amgen Inc are currently held by insiders. Unlike Amgen's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Amgen's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Amgen's insider trades
Amgen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amgen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amgen Inc backward and forwards among themselves. Amgen's institutional investor refers to the entity that pools money to purchase Amgen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 5.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 5.4 M | Goldman Sachs Group Inc | 2024-06-30 | 5.2 M | Royal Bank Of Canada | 2024-06-30 | 5 M | Legal & General Group Plc | 2024-06-30 | 4.8 M | Hhg Plc | 2024-06-30 | 4.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 4.5 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 4.4 M | Fmr Inc | 2024-09-30 | 4.2 M | Vanguard Group Inc | 2024-09-30 | 52.4 M | Blackrock Inc | 2024-06-30 | 46 M |
Amgen Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amgen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amgen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amgen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amgen's latest congressional trading
Congressional trading in companies like Amgen Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Amgen by those in governmental positions are based on the same information available to the general public.
| 2024-11-11 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-10-10 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2024-10-09 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-08-20 | Representative C Scott Franklin | Acquired Under $15K | Verify | ||
| 2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
| 2024-02-14 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
| 2024-02-13 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
| 2019-10-07 | Representative Bill Flores | Acquired Under $15K | Verify | ||
| 2017-06-07 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
| 2017-01-11 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2017-01-10 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2015-03-02 | Senator John Reed | Acquired Under $15K | Verify | ||
| 2014-07-17 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2014-07-16 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify |
Amgen Outstanding Bonds
Amgen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Amgen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Amgen bonds can be classified according to their maturity, which is the date when Amgen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AMGEN INC 515 Corp BondUS031162BK53 | View | |
| AMGEN INC 3125 Corp BondUS031162BY57 | View | |
| AMGEN INC 44 Corp BondUS031162BZ23 | View | |
| AMGEN INC 4663 Corp BondUS031162CF59 | View | |
| AMGEN INC 4563 Corp BondUS031162CD02 | View | |
| AMGEN INC 26 Corp BondUS031162CJ71 | View | |
| AMGEN INC 6375 Corp BondUS031162AW01 | View | |
| AMGEN INC 64 Corp BondUS031162BA71 | View |
Amgen Corporate Filings
F4 | 6th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 23rd of August 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.61 | A | Agilent Technologies Earnings Call Today | PairCorr |
| 0.79 | ME | 23Andme Holding | PairCorr |
| 0.7 | VALN | Valneva SE ADR | PairCorr |
| 0.8 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Amgen Stock
| 0.46 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.41 | KZR | Kezar Life Sciences | PairCorr |
| 0.39 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.83 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.